Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer. [electronic resource]
Producer: 20180103Description: 1141-1149 p. digitalISSN:- 1473-5741
- Aniline Compounds -- administration & dosage
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Drug Synergism
- Humans
- Lung Neoplasms -- drug therapy
- MAP Kinase Signaling System -- drug effects
- Male
- Mice
- Mice, Nude
- Molecular Targeted Therapy
- Phosphoinositide-3 Kinase Inhibitors
- Protein Kinase Inhibitors -- administration & dosage
- Proto-Oncogene Proteins c-akt -- antagonists & inhibitors
- Proto-Oncogene Proteins c-bcl-2 -- antagonists & inhibitors
- Random Allocation
- Stomach Neoplasms -- drug therapy
- Sulfonamides -- administration & dosage
- Up-Regulation
- Xenograft Model Antitumor Assays
- bcl-X Protein -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.